Eyeworld

EW CATARACT 32 June 2017 Four-year results Dr. Piovella's study included 111 eyes of 67 patients with a mean age of 67.17 ± 11.46 years that underwent uncomplicated cataract surgery with phacoemulsification and trifocal IOL implantation. Pre- loaded IOLs were implanted using a BLUEMIXS 180 injector (Carl Zeiss Meditec) for a 2.4 corneal incision. Postoperatively, the following visual and refractive parameters were mea- sured: distance vision at 5 m, near vision at 40 cm, and intermediate vision at 80 cm, corneal topography, aberrometry, contrast sensitivity, and defocus curve. Regular follow-up examinations were performed up to 4 years after surgery. Biometry was carried out with special attention to those patients with dry eye, to ensure precise measurements. Preoperatively, the mean distance uncorrected visual acui- ty (UCVA) was 20/125. At 4 years, distance UCVA was 20/20, monocu- lar and binocular uncorrected near visual acuity (UNVA) and uncorrect- ed intermediate visual acuity (UIVA) were 20/32. "After 4 years' experience with trifocal IOLs, trifocal technology has been applied in 73% of the patients that underwent cataract surgery in our surgical center. Of these, 94% of eyes achieved postoperative refrac- tive results within ± 0.50 D spherical equivalent," Dr. Piovella said. "The AT LISA tri 839MP provided good distance and near as well as inter- mediate visual acuity. This lens also provided a high quality of vision and remarkable diffractive effica- cy, with a low impact on contrast sensitivity. Our patients have never reported night time driving difficul- ties, and in 4 years of experience, we never needed to explant a single lens. The AT LISA 839MP is our first choice IOL to correct presbyopia in cataract patients because of the ex- cellent technology and outcomes. It is the bifocal IOL replacement." EW Editors' note: Dr. Webers has no finan- cial interests related to his comments. Dr. Piovella has financial interests with Johnson & Johnson Vision (Santa Ana, California), AcuFocus (Irvine, Califor- nia), Carl Zeiss Meditec, TearLab (San Diego), Beaver-Visitec International (Waltham, Massachusetts), Ocular Therapeutix (Bedford, Massachusetts), and TearScience (Morrisville, North Carolina). Contact information Piovella: piovella@piovella.com Webers: Valentijn.webers@mumc.nl According to Matteo Piovella, MD, medical director, Centro Mi- crochirurgia Ambulatoriale, Monza, Italy, who presented the study, the refractive surgeon needs to base his IOL choice on the latest IOL tech- nology and high precision biometry. "Trifocal IOLs and extended depth of focus IOLs have replaced bifo- cal technology. The limitations of bifocal IOLs include the very high patient sensitivity to more than ±0.5 D postoperative refractive error out- comes, which is a small amount of postoperative refractive error. Bifocal IOLs don't provide intermediate vision. Trifocals are less sensitive to a small amount of postoperative refractive error, provide intermediate and distance vision, and are the best available near vision correction. It is up to eye surgeons to select the IOL for our patients because we understand which indications allow a smooth transition to presbyopic IOLs. The diffractive technology is the most important consideration. We get the best results by applying high standard biometry that gives us high precision results for the IOL calculation. We know eyes better than our patients." AUGUST 10TH, 2017 BOSTON, MA SHERATON BOSTON HOTEL NOVEMBER 9TH, 2017 NEW ORLEANS, LA HYATT REGENCY NEW ORLEANS OIS.NET SIGN UP TODAY! UPCOMING EVENTS UNITING THE LEADERS IN THE DEVELOPMENT OF GROUND-BREAKING OPHTHALMIC TECHNOLOGIES. I love OIS, nothing else comes close in presenting the total picture of Ophthalmology with all of it's Business, Financing and Strategy. The Ophthalmology Innovation Summit is for me the highlight of both the ASCRS and AAO Meetings. This meeting is packed with useful information for the ophthalmologist, industry executive and investor that is simply not available in any other venue. I consider OIS to be a cannot miss meeting. Richard Lindstrom, MD Stephen Slade, MD Cutting-edge continued from page 30

• Blank Page
• Blank Page (1)